13D Filing: Farallon Capital and Radius Health Inc. (RDUS)

(ix)

Farallon Capital Management, L.L.C., a Delaware limited liability company (the “Management Company“), with respect to the Shares held by one or more accounts (the “Managed Accounts“), each as managed by the Management Company.

Farallon Partners, L.L.C., a Delaware limited liability company (the “Farallon General Partner“), which is the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of the FCIP V General Partner (as defined below), with respect to the Shares held by each of the Farallon Funds other than F5MI.

(xi)

Farallon Institutional (GP) V, L.L.C., a Delaware limited liability company (the “FCIP V General Partner“), which is the general partner of FCIP V, with respect to the Shares held by FCIP V.

(xii)

Farallon F5 (GP), L.L.C., a Delaware limited liability company (the “F5MI General Partner“), which is the general partner of F5MI, with respect to the Shares held by F5MI.

The following persons, each of whom is a managing member of both the Farallon General Partner and the Management Company, a manager or senior manager, as the case may be, of the FCIP V General Partner and a director and/or officer of the general partner of the sole member of the F5MI General Partner, with respect to the Shares held by the Farallon  Funds and the Managed Accounts:  Philip D. Dreyfuss (“Dreyfuss“), Michael B. Fisch (“Fisch“), Richard B. Fried (“Fried“), David T. Kim (“Kim“), Monica R. Landry (“Landry“), Michael G. Linn (“Linn“), Ravi K. Paidipaty (“Paidipaty“), Rajiv A. Patel (“Patel“), Thomas G. Roberts, Jr. (“Roberts“), William Seybold (“Seybold“), Andrew J.M. Spokes (“Spokes“), John R. Warren (“Warren“) and Mark C. Wehrly (“Wehrly“).